Multivalent display of heterologous proteins on viral nanoparticles forms a basis for numerous applications in nanotechnology, including vaccine development, targeted therapeutic delivery, and tissue-specific bioimaging. In many instances, precise placement of proteins is required for optimal functioning of the supramolecular assemblies, but orientation- and site-specific coupling of proteins to viral scaffolds remains a significant technical challenge. We have developed two strategies that allow for controlled attachment of a variety of proteins on viral particles using covalent and noncovalent principles. In one strategy, an interaction between domain 4 of anthrax protective antigen and its receptor was used to display multiple copies of a target protein on virus-like particles. In the other, expressed protein ligation and aniline-catalyzed oximation was used to display covalently a model protein. The latter strategy, in particular, yielded nanoparticles that induced potent immune responses to the coupled protein, suggesting potential applications in vaccine development.
Multivalent display of heterologous proteins on viral nanoparticles forms a basis for numerous applications in nanotechnology, including vaccine development, targeted therapeutic delivery, and tissue-specific bioimaging. In many instances, precise placement of proteins is required for optimal functioning of the supramolecular assemblies, but orientation- and site-specific coupling of proteins to viral scaffolds remains a significant technical challenge. We have developed two strategies that allow for controlled attachment of a variety of proteins on viral particles using covalent and noncovalent principles. In one strategy, an interaction between domain 4 of pan class="Species">anthrax protective antigen and its receptor was used to display multiple copies of a target protein on virus-like particles. In the other, expressed protein ligation and span>n class="Chemical">aniline-catalyzed oximation was used to display covalently a model protein. The latter strategy, in particular, yielded nanoparticles that induced potent immune responses to the coupled protein, suggesting potential applications in vaccine development.
Authors: Andrea Jegerlehner; Alain Tissot; Franziska Lechner; Peter Sebbel; Iris Erdmann; Thomas Kündig; Thomas Bächi; Tazio Storni; Gary Jennings; Paul Pumpens; Wolfgang A Renner; Martin F Bachmann Journal: Vaccine Date: 2002-08-19 Impact factor: 3.641
Authors: Heather M Scobie; G Jonah A Rainey; Kenneth A Bradley; John A T Young Journal: Proc Natl Acad Sci U S A Date: 2003-04-16 Impact factor: 11.205
Authors: Darran J Wigelsworth; Bryan A Krantz; Kenneth A Christensen; D Borden Lacy; Stephen J Juris; R John Collier Journal: J Biol Chem Date: 2004-03-24 Impact factor: 5.157
Authors: Heather M Scobie; Darran J Wigelsworth; John M Marlett; Diane Thomas; G Jonah A Rainey; D Borden Lacy; Marianne Manchester; R John Collier; John A T Young Journal: PLoS Pathog Date: 2006-10 Impact factor: 6.823
Authors: Gregory A Hudalla; Justin A Modica; Ye F Tian; Jai S Rudra; Anita S Chong; Tao Sun; Milan Mrksich; Joel H Collier Journal: Adv Healthc Mater Date: 2013-02-25 Impact factor: 9.933
Authors: Michael B Deci; Scott W Ferguson; Maixian Liu; Damian C Peterson; Sujatha P Koduvayur; Juliane Nguyen Journal: Biomaterials Date: 2016-08-28 Impact factor: 12.479
Authors: Laura E Richert; Amy E Servid; Ann L Harmsen; Agnieszka Rynda-Apple; Soo Han; James A Wiley; Trevor Douglas; Allen G Harmsen Journal: Vaccine Date: 2012-03-28 Impact factor: 3.641